C4 Therapeutics Files 8-K
Ticker: CCCC · Form: 8-K · Filed: Oct 1, 2025 · CIK: 1662579
| Field | Detail |
|---|---|
| Company | C4 Therapeutics, Inc. (CCCC) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials, corporate-events
TL;DR
C4 Therapeutics filed an 8-K on Oct 1, 2025, covering disclosures and financials.
AI Summary
C4 Therapeutics, Inc. filed an 8-K on October 1, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, incorporated in Delaware, is in the biological products sector and is headquartered in Watertown, MA.
Why It Matters
This 8-K filing provides updates on C4 Therapeutics' corporate activities and financial reporting, which are important for investors to monitor the company's status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.
Key Numbers
- 001-39567 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-5617627 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- C4 Therapeutics, Inc. (company) — Registrant
- October 1, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Watertown, MA (location) — Principal Executive Offices
FAQ
What specific events are disclosed under Regulation FD Disclosure?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the excerpt.
What are the 'Other Events' reported in this 8-K?
The filing lists 'Other Events' as an item, but the specific nature of these events is not detailed in the provided text.
What type of financial statements and exhibits are included?
The filing mentions 'Financial Statements and Exhibits' as an item, but the content of these statements and exhibits is not specified in the excerpt.
When was C4 Therapeutics, Inc. incorporated?
C4 Therapeutics, Inc. was incorporated in Delaware.
What is the primary business of C4 Therapeutics, Inc. according to the SIC code?
According to the Standard Industrial Classification code [2836], C4 Therapeutics, Inc. is in the business of Biological Products (no diagnostic substances).
Filing Stats: 721 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2025-10-01 07:06:28
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Glo
Filing Documents
- cccc-20251001.htm (8-K) — 30KB
- cccc-20251001xexx991.htm (EX-99.1) — 11KB
- c4tlogo1.jpg (GRAPHIC) — 9KB
- 0001628280-25-043290.txt ( ) — 174KB
- cccc-20251001.xsd (EX-101.SCH) — 2KB
- cccc-20251001_lab.xml (EX-101.LAB) — 22KB
- cccc-20251001_pre.xml (EX-101.PRE) — 13KB
- cccc-20251001_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 1, 2025, C4 Therapeutics, Inc. (the " Company ") issued a press release announcing that the Company had entered into a clinical trial collaboration and supply agreement (the " Agreement ") with Pfizer Inc. (" Pfizer "). A copy of this press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.
01 Other Events
Item 8.01 Other Events. On October 1, 2025, the Company announced that it had entered into the Agreement with Pfizer. Under the terms of the Agreement, Pfizer will supply elranatamab (ELREXFIO ), a B-cell maturation antigen CD3 targeted bispecific antibody (BCMAxCD3 bispecific), to the Company for its upcoming Phase 1b trial evaluating the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab as a second line or later therapy for patients with multiple myeloma. Pursuant to the Agreement, Pfizer will supply elranatamab to the Company at no cost in exchange for access to data from the trial, while the Company will sponsor and conduct the trial.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. Exhibit Number Description 99.1 Press release issued October 1, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. C4 Therapeutics, Inc. Date: October 1, 2025 By: /s/ Jolie M. Siegel Jolie M. Siegel Chief Legal Officer and Secretary